IN2012DN03337A - - Google Patents

Info

Publication number
IN2012DN03337A
IN2012DN03337A IN3337DEN2012A IN2012DN03337A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A IN 3337DEN2012 A IN3337DEN2012 A IN 3337DEN2012A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A
Authority
IN
India
Prior art keywords
compounds
formula
well
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
Inventor
Jean Ackermann
Stephan Brugger
Aurelia Conte
Daniel Hunziker
Werner Neidhart
Matthias Nettekoven
Tanja Schulz-Gasch
Stanley Wertheimer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03337A publication Critical patent/IN2012DN03337A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54Spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein R1 ,R2, R3 , Ca and Cb have the significance given in claim 1.
IN3337DEN2012 2009-10-15 2010-10-12 IN2012DN03337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09173178 2009-10-15
PCT/EP2010/065232 WO2011045292A1 (en) 2009-10-15 2010-10-12 Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
IN2012DN03337A true IN2012DN03337A (en) 2015-10-23

Family

ID=43093680

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3337DEN2012 IN2012DN03337A (en) 2009-10-15 2010-10-12

Country Status (20)

Country Link
US (1) US8440710B2 (en)
EP (1) EP2488493B1 (en)
JP (1) JP5749272B2 (en)
KR (1) KR101576328B1 (en)
CN (1) CN102858743B (en)
AR (1) AR078619A1 (en)
AU (1) AU2010305859A1 (en)
BR (1) BR112012008962A2 (en)
CA (1) CA2776457A1 (en)
CL (1) CL2012000937A1 (en)
ES (1) ES2538005T3 (en)
HK (1) HK1179957A1 (en)
IL (1) IL218958A0 (en)
IN (1) IN2012DN03337A (en)
MX (1) MX2012004311A (en)
PE (1) PE20121732A1 (en)
RU (1) RU2607080C2 (en)
TW (1) TW201118068A (en)
WO (1) WO2011045292A1 (en)
ZA (1) ZA201202613B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201190138A1 (en) 2009-03-23 2013-05-30 Гленмарк Фармасьютикалс, С.А. FUROPYRIMIDINDION DERIVATIVES AS TRPA1 MODULATORS
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
CN103319395B (en) * 2013-04-08 2014-09-24 武汉罗化科技有限公司 Industrialization preparation method for 4-fluoroisatin and product thereby
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
UY36060A (en) 2014-04-02 2015-10-30 Bayer Pharma AG AZOL COMPOUNDS REPLACED WITH AMIDA
CA3079833A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
JP7264906B2 (en) 2017-11-01 2023-04-25 ブリストル-マイヤーズ スクイブ カンパニー Alkene compounds as farnesoid X receptor modulators
CN111630051B (en) 2017-11-01 2023-12-26 百时美施贵宝公司 Olefin spiro compounds as farnesol X receptor modulators
MX2020004400A (en) 2017-11-01 2020-08-06 Bristol Myers Squibb Co Spirocyclic compounds as farnesoid x receptor modulators.
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
CN109369354B (en) * 2018-12-15 2021-07-09 浦拉司科技(上海)有限责任公司 Synthesis method of 4,4, 4-trifluorobutanol
AR118050A1 (en) 2019-02-15 2021-09-15 Bristol Myers Squibb Co BICYCLIC COMPOUNDS REPLACED AS MODULATORS OF THE FARNESOID X RECEIVER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247680B4 (en) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh New bicyclic inhibitors of the hormone sensitive lipase
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20070135457A1 (en) 2003-12-16 2007-06-14 Pfizer Inc. Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors
FR2870538B1 (en) * 2004-05-19 2006-07-14 Servier Lab NOVEL DERIVATIVES OF PYRROLIDINES AND THIAZOLIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CA2648019C (en) * 2006-04-25 2014-04-01 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DK2021337T3 (en) * 2006-04-25 2010-03-29 Lilly Co Eli Inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1

Also Published As

Publication number Publication date
TW201118068A (en) 2011-06-01
ES2538005T3 (en) 2015-06-16
AR078619A1 (en) 2011-11-23
CA2776457A1 (en) 2011-04-21
CN102858743A (en) 2013-01-02
IL218958A0 (en) 2012-06-28
BR112012008962A2 (en) 2019-09-24
AU2010305859A1 (en) 2012-06-07
EP2488493A1 (en) 2012-08-22
RU2012119706A (en) 2013-11-20
CN102858743B (en) 2015-06-10
HK1179957A1 (en) 2013-10-11
KR101576328B1 (en) 2015-12-10
ZA201202613B (en) 2013-01-30
KR20120074304A (en) 2012-07-05
JP5749272B2 (en) 2015-07-15
CL2012000937A1 (en) 2012-09-14
US8440710B2 (en) 2013-05-14
WO2011045292A1 (en) 2011-04-21
RU2607080C2 (en) 2017-01-10
MX2012004311A (en) 2012-04-30
JP2013507421A (en) 2013-03-04
PE20121732A1 (en) 2012-12-28
EP2488493B1 (en) 2015-04-15
US20110092512A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
IN2012DN03337A (en)
MX2010005824A (en) Aminothiazole derivatives.
TW200738241A (en) Pyridazine derivatives
MY138941A (en) Aryl-pyridine derivatives
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
MX2011012017A (en) Azacyclic spiroderivatives as hsl inhibitors.
TW200616976A (en) Pyrimidine derivatives
UA108105C2 (en) Nitrogen-containing heteroaryl compounds
IN2012DN01232A (en)
MX2012000414A (en) Pyridin-4-yl derivatives.
MX2009003939A (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes.
IN2012DN01233A (en)
TW200740764A (en) Pyrazolone derivatives
MY153921A (en) Aminopyrazole derivatives
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
UA109037C2 (en) Triazolepyridins
MX2010005714A (en) Pyridine compounds.
MX2008016426A (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1).
UA102310C2 (en) Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions
IN2012DN00765A (en)
MX2009013501A (en) Piperidine compounds and uses thereof.
MX2011008360A (en) Heteroaryl substituted pyridazinone derivatives.
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MX2009003169A (en) Sulfonamide derivatives.